Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing.It was established in 1994 and is headquartered in Lexington, Massachusetts.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 4, 2009 | Post-IPO Equity | $10M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Downsview Capital | — | Post-IPO Equity |